![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Translarna |
Other names | PTC124 |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.132.097 |
Chemical and physical data | |
Formula | C15H9FN2O3 |
Molar mass | 284.246 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.